Methylation of the hMLH1 gene promoter is observed in many tumour types (Strathdee et al, 1999; Gifford et al, 2004) and loss of MLH1 expression is associated with clinical drug resistance in ovarian cancer (Samimi et al, 2000). This evidence concerns the gene MLH1 and ovarian carcinoma.